PT  - JOURNAL ARTICLE
AU  - Pedapati, Ernest V
AU  - Schmitt, Lauren M.
AU  - Liu, Rui
AU  - Ethridge, Lauren E.
AU  - Smith, Elizabeth
AU  - Sweeney, John A
AU  - Shaffer, Rebecca C.
AU  - Dominick, Kelli C.
AU  - Gilbert, Donald L.
AU  - Wu, Steve W.
AU  - Horn, Paul S.
AU  - Binder, Devin
AU  - Lamy, Martine
AU  - Axford, Megan
AU  - Miyakoshi, Makoto
AU  - Erickson, Craig A.
TI  - Neocortical Localization and Thalamocortical Modulation of Neuronal Hyperexcitability in Fragile X Syndrome
AID  - 10.1101/2021.05.12.21256925
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.05.12.21256925
4099  - http://medrxiv.org/content/early/2021/05/13/2021.05.12.21256925.short
4100  - http://medrxiv.org/content/early/2021/05/13/2021.05.12.21256925.full
AB  - Fragile X Syndrome (FXS) is a monogenetic form of intellectual disability and autism in which well-established knockout (KO) animal models point to neuronal hyperexcitability and abnormal gamma-frequency physiology as a basis for key illness features. Translating these findings into patients may identify tractable treatment targets. Using a minimum norm estimate of resting state electroencephalography data, we report novel findings in FXS including: 1) increases in gamma activity across functional networks, 2) pervasive changes of theta/alpha activity, indicative of disrupted thalamocortical modulation coupled with elevated gamma power, 3) stepwise moderation of these abnormalities based on female sex and genetic mosaicism, and 4) relationship of this physiology to intellectual disability and anxiety. Our observations extend findings in Fmr1-/- KO mice to patients with FXS and raise a key role for disrupted thalamocortical modulation in local hyperexcitability, a mechanism that has received limited preclinical attention, but has significant implications for understanding fundamental disease mechanisms.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02998151Funding StatementThe present study was federally funded by National Institutes of Health (NIH) Fragile X Center (U54HD082008).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Cincinnati Childrens Hospital Medical Board approved the conduct of the study. All participants provided written informed consent (or assent as appropriate) prior to participation.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesEEG data is available to the public as federally mandated at the National Database for Autism Research (NDAR). Analysis code is in preparation for upload into public repositories and is available on request. https://nda.nih.gov/edit_collection.html?id=2373